Regeneron Pharmaceuticals today announced the results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed the use of a single dose of investigational REGEN-COV, a monoclonal antibodies drug, to prevent COVID-19 in uninfected individuals.
The new analyses show REGEN-COV reduced the risk of contracting COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.6% during the pre-specified follow-up period (months 2-8) ... Read even more
